The development of small molecule antivirals that target viral RNA in Henipaviruses will benefit from a $1.7million grant from Open Philanthropy, a philanthropic funder prioritizing global health and wellbeing.
The biotech company emerges with financial banking to support its 3D RNA structure engine.
SanegeneBio has formed a service agreement with Orbit Discovery to support tissue-specific delivery of a wide range of RNA therapeutics.
Novartis has recently set up a new contract development and manufacturing unit called Global Biotech Co-operations (GBTC).
Skyhawk enters an agreement with Merck to discover and develop small molecules to modulate RNA splicing, and expands its existing development agreement with Biogen.
Novartis exercises its option to license Ionis’ RNA-targeting cardiovascular drug, adding to its cardiovascular treatment portfolio, as Entresto reaches the three-year mark on its patent.
Scipher announced positive outcomes of its retrospective trial for its test Prism used to predict clinical utility, with data predicting it could double patients’ response rate to major therapies.
VGXI, a subsidiary of GeneOne, signed a licensing agreement with Houston Methodist Research Institute to produce RNA one of the most valued clinical ingredients.
Arbutus Biopharma Corporation is cutting operations but says it remains committed to developing its messenger RNA drug delivery technology.
AstraZeneca has entered a five-year collaboration to develop therapies for respiratory diseases based on Ethris’ messenger RNA (mRNA) technology.
Alexion Pharmaceuticals will use the LNP delivery licensed from Arbutus Biopharma as part of its messenger RNA therapeutics development partnership with Moderna Therapeutics.
Alnylam’s RNAi manufacturing plant will be operational by 2018 and the firm says it is willing to invest in a second facility depending on its pipeline success.
Alnylam has acquired 12 acres of land in Massachusetts in anticipation of building a manufacturing facility for its RNA interference therapies.
Roche has renewed its interest in gene silencing drugs, paying $250m (€187m) for Santaris Pharma including its ‘antisense’ Locked Nucleic Acid (LNA) platform.
Bayer has inked a deal with preclinical CRO Cenix BioScience to use its genome-scale RNA interference (RNAi) platform to target an undisclosed disease.
RNA interference (RNAi) developers that saw stock prices fall after Novartis pulled out of the market last week have reiterated their belief in the therapeutic and revenue potential of gene silencing drugs.
Merck & Co.’s divestiture of its RNA interference business (RNAi) was part of a strategy to cut $2.5bn and focus on core areas, according to its CEO.
Solstice Biologics says its new “limitless” RNAi technology will win back Big Pharmas previously put off by delivery difficulties.
Delivery vehicles can revitalise RNAi sector; AAPS panel
Aptamers and dendrimers can revitalise the faltering siRNA sector by solving delivery problems, AAPS panelists said.
Life Technologies improves siRNA technology 100-fold
Life Technologies has developed new drug delivery technology for therapeutic applications that is 100 times more potent than previous formulations.
Marina buys Smarticles liposomal delivery system
Marina Biotech has acquired the intellectual property for the Smarticles liposomal-based delivery system from Novosom AG.
Philips and RXI partner to research RNAi delivery
Philips and RXi Pharmaceuticals have formed a research agreement to investigate combining their technologies for delivery of RNA interference (RNAi).
Natural drug delivery system aids cancer therapeutics
New research could make it possible for scientists to use silicon particles as an effective drug delivery system that enables fragile small interfering RNA (siRNA) based drugs to be directly transported to the disease’s location.
Pfizer and Tekirma team on siRNA delivery
US drug giant Pfizer will assess Tekimra Pharmaceuticals’s stable nucleic acid-lipid particle (SNALP) platform for the delivery of siRNA drugs.
MDRNA’s formulation stable after 12 months
MDRNA’s liposomal drug delivery formulation, DiLA2, lost no potency when stored for 12 months in conditions ranging from -80ºC to 4ºC, helping to validate it for administration of UsiRNA.
US PTO approves Isis and Alnylam’s new RNAi claims
US drugmakers developers Isis and Alnylam say the US PTO has allowed 75 new claims relating to the development of RNAi drugs.
MDRNA signs deal with second Swiss major
US RNA interference (RNAi) specialist MDRNA has signed a non-exclusive licensing deal granting Swiss drug giant Novartis access to its liposomal siRNA delivery technology platform.
Abbott PRINT’s map to siRNA delivery
Abbott Laboratories has licensed Liquidia Technologies’ PRINT nanoparticle technology for the delivery of siRNA-based therapeutics, which have the potential to improve the company’s cancer portfolio.
RNAi therapeutics market hots up
Novartis’ extension of its collaboration with Alnylam Therapeutics and Roche’s acquisition of gene silencing specialist Mirus Bio Corp for $125m (€78.5m) suggest that big pharma is beginning to recognize the commercial potential of RNAi-based therapeutics.
Bio-Rad keeps your genes silenced for longer
Bio-Rad has launched a new web-based search tool to give researchers easier access to its validated siLentMer gene silencing product line, which offers up to twice the silencing longevity.
Thermo expands RNAi offering with Open Bio purchase
Laboratory industry heavyweight, Thermo Fisher Scientific has
acquired shRNA expert Open Biosystems to expand its gene silencing
Artificial virus for 'tailor-made gene therapy'
An artificial self-assembling virus capable of serving as a drug
delivery system has been created by researchers in Korea, according
to a publication in Angewandte Chemie.
Agilent announces second expansion at API plant
Agilent Technologies is expanding its nucleic acid active
pharmaceutical ingredient (API) manufacturing facility in Boulder,
Colorado, US, as the industry gravitates towards the
development of oligonucleotide-based drugs.
Febit upgrades miRNA microarrays with new Sanger database
Febit has updated its Geniom microRNA analysis platform with the
latest version of the Sanger Institute's database of all known
miRNA elements. The upgrade should provide scientists with a more
detailed microRNA profile of their...
Thermo Fisher claims breakthrough with gene-silencing agent
Research into the use of RNA interference (RNAi) to "silence" gene
activity has taken another step forwards, saysThermo Fisher
Scientific which has launched an agent that accelerates the
processes in which RNAi is used to...
Biomatrica storage solution keeps RNA fresh
Biomatrica has launched the RNAstable - a piece of kit that
preserves RNA samples at ambient and elevated temperatures with
Sigma-Aldrich helps siRNA N-TER cells
Sigma-Aldrich has continued its push into siRNA delivery
with the release of its N-TER nanoparticle system for
hard-to-transfect cell lines.
Illumina halves the cost of miRNA expression profiling
Illumina has released a new microRNA (miRNA) assay for gene
expression profiling at a cost that the company believes is less
than half that of other commercially available systems.
New bull's-eye for obesity fighting drugs
Drug developers have a new target to aim at in the fight against
obesity after the discovery that a certain protein in the body
stimulates the formation of fat cells.
Isis and Alnylam launch microRNA spin-out
Two specialists in the field of RNA-based drug discovery have
decided to launch a joint spin-out company to focus solely on
microRNA (miRNA) research.
Asuragen moves ahead with microRNA offering
Asuragen has launched a newly expanded miRNA expression profiling
service that can search over 13,000 human candidate miRNAs.
ABI launches new miRNA expression arrays
Applied Biosystems (ABI) has launched its TaqMan microRNA (miRNA)
assays in array format to help researchers search for miRNA
biomarkers more efficiently from smaller samples.
IDT simplifies miRNA discovery with miRCat launch
Integrated DNA Technologies (IDT) has launched a new kit for
cloning libraries of small RNAs from any primary RNA source to
enable the discovery of new small RNA molecules.
Anacor's boron-based drug stops the rot
An unusual drug that contains a crucial boron atom can effectively
treat fungal infections, and could also prove invaluable in the
effort to counter antibacterial drug resistance.
Agilent launch first microarray assay for miRNA
The first commercially available microarray based assay for
microRNA (miRNA) has been launched by Agilent to aid in drug
discovery research programs.
RNA 'switch' could turn off cancer
Scientists have discovered a piece of 'junk' genetic material that
could switch off cancer tumours, preventing them from growing.
Delivery technology 'could speed up siRNA development'
US researchers have developed a novel delivery vehicle for siRNA,
an up-and-coming technology for switching off genes in the body
that could accelerate its use in drug development.
Alnylam receives small interfering RNA therapeutics patent
Alnylam has been issued a US patent, which protects its method of
making small interfering RNAs with and without chemical
modifications, which is set to have far reaching implications in
future drug discovery.
SR Pharma contracts its way forward in siRNA production
SR Pharma has recruited Genzyme, BioSpring and OctoPlus to
formulate and manufacture its lead RNAi therapeutic product Atu027
to good manufacturing practice (GMP) standards, as its liposomal
drug delivry system moves forward.
SR Pharma claims formulation triumph in siRNA drugs
Biotechnology firm SR Pharma has announced a technical breakthrough
in the formulation of siRNA drugs, enabling them to be stored at
room temperature and reconstituted in one simple step, thus
extending shelf life and making administration...